Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
- PMID: 37290798
- DOI: 10.2967/jnumed.123.265471
Evaluation of the Diagnostic Accuracy of FAPI PET/CT in Oncologic Studies: Systematic Review and Metaanalysis
Abstract
Fibroblast-activation protein is a promising target for oncologic molecular imaging. Studies show that fibroblast activation protein inhibitor (FAPI) radiotracers are accurate diagnostics with favorable tumor-to-background ratios across various cancers. Therefore, we performed a systematic review and metaanalysis to assess the diagnostic performance of FAPI PET/CT in comparison with [18F]FDG PET/CT, the most widely used radiotracer in oncology. Methods: We conducted a systematic search in MEDLINE, Embase, Scopus, PubMed, Cochrane Central Register of Controlled Trials, relevant trial registries, and bibliographies. The search consisted of combinations of terms for 3 topics: neoplasia, PET/CT, and FAPI. Two authors independently screened retrieved articles using predefined inclusion and exclusion criteria and extracted the data. Study quality was assessed using the criteria of QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2). For each study, the sensitivity, specificity, and 95% CIs were calculated to determine diagnostic accuracy for primary, nodal, and metastatic lesions. A random-effects metaanalysis was used for pooling the data, and heterogeneity was assessed (I2 index). Results: Thirty-nine studies (1,259 patients) investigating the use of FAPI PET/CT were included. On a patient-based analysis, pooled sensitivity was 0.99 (95% CI, 0.97-1.0) for the detection of primary lesions. Pooled sensitivity for nodal and distant metastases was 0.91 (95% CI, 0.81-0.96) and 0.99 (95% CI, 0.96-1.0), respectively. On a paired analysis between FAPI and [18F]FDG PET/CT, FAPI had a higher sensitivity in the detection of primary, nodal, and metastatic lesions (all P < 0.001). The differences in sensitivities between FAPI and [18F]FDG were statistically significant. In terms of heterogeneity, analyses on primary lesions were moderately affected, distant metastatic lesions were highly affected, and the nodal metastatic analyses had negligible heterogeneity. Conclusion: The diagnostic performance of FAPI PET/CT is superior to that of [18F]FDG in the detection of primary, nodal, and distant metastases. However, further studies are needed to better evaluate its utility and indication in specific cancer types and clinical settings.
Keywords: FAPI; PET/CT; metaanalysis; neoplasia; radiology.
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Similar articles
-
Diagnostic value of 18F-FDG PET/CT and 68Ga-FAPI PET/CT in primary liver cancer: A systematic review and meta-analysis.Hell J Nucl Med. 2023 May-Aug;26(2):123-131. doi: 10.1967/s002449912575. Epub 2023 Aug 4. Hell J Nucl Med. 2023. PMID: 37527048
-
Head to head comparison of 68Ga-FAPI PET/CT with 18F-FDG PET/CT in primary and metastatic lesions of gastric tumor: A systematic review and meta-analysis.Hell J Nucl Med. 2024 Jan-Apr;27(1):35-45. doi: 10.1967/s002449912703. Epub 2024 Apr 18. Hell J Nucl Med. 2024. PMID: 38629816
-
The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):963-979. doi: 10.1007/s00259-021-05522-w. Epub 2021 Aug 19. Eur J Nucl Med Mol Imaging. 2022. PMID: 34410435
-
Performance of [18F]FDG PET/CT versus FAPI PET/CT for lung cancer assessment: a systematic review and meta-analysis.Eur Radiol. 2024 Feb;34(2):1077-1085. doi: 10.1007/s00330-023-10013-7. Epub 2023 Aug 17. Eur Radiol. 2024. PMID: 37589901
-
FAPI Compared with FDG PET/CT for Diagnosis of Primary and Metastatic Lung Cancer.Radiology. 2023 Aug;308(2):e222785. doi: 10.1148/radiol.222785. Radiology. 2023. PMID: 37552075
Cited by
-
Multitracer comparison of gold standard PSMA-PET/CT with 68Ga-FAPI and 18F-FDG in high-risk prostate cancer: a proof-of-concept study.Eur J Nucl Med Mol Imaging. 2025 May 27. doi: 10.1007/s00259-025-07352-6. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40423777
-
Biomarker-driven molecular imaging probes in radiotherapy.Theranostics. 2024 Jul 2;14(10):4127-4146. doi: 10.7150/thno.97768. eCollection 2024. Theranostics. 2024. PMID: 38994026 Free PMC article. Review.
-
Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics.Pharmaceuticals (Basel). 2025 Apr 3;18(4):522. doi: 10.3390/ph18040522. Pharmaceuticals (Basel). 2025. PMID: 40283957 Free PMC article. Review.
-
[68Ga]Ga-FAPI PET/CT in brain tumors: comparison with [18F]F-FDG PET/CT.Front Oncol. 2024 Sep 6;14:1436009. doi: 10.3389/fonc.2024.1436009. eCollection 2024. Front Oncol. 2024. PMID: 39309741 Free PMC article.
-
From FDG and beyond: the evolving potential of nuclear medicine.Ann Nucl Med. 2023 Nov;37(11):583-595. doi: 10.1007/s12149-023-01865-6. Epub 2023 Sep 25. Ann Nucl Med. 2023. PMID: 37749301 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources